International Journal of Colorectal Disease

, Volume 33, Issue 11, pp 1595–1600 | Cite as

Flavonoid mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) in the treatment of I–III degree hemorroidal disease: a double-blind multicenter prospective comparative study

  • Italo CorsaleEmail author
  • Paolo Carrieri
  • Jacopo Martellucci
  • Alessandro Piccolomini
  • Luigi Verre
  • Marco Rigutini
  • Sonia Panicucci
Original Article



We evaluated the efficacy of new flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) to reduce bleeding from I–III degrees hemorrhoidal disease in the short and medium time.


One hundred fifty-four consecutive patients with hemorrhoidal disease recruited in four colorectal units were enrolled to the study. Exclusion criteria were allergy to the flavonoids, inflammatory bowel disease, obstructed defecation syndrome, pregnancy and puerperium, associated anal disease or hemorrhoidal thrombosis, proctologic surgical procedures within 1 year before recruitment, contemporary cancer or HIV, previous pelvic radiotherapy, patients receiving oral anticoagulant therapy, or contemporary administration of other therapy for hemorrhoids. Patients with inability to understand the study or mental disorders were also excluded.


Seventy-eight were randomized to receive the mixture of diosmin, troxerutin, rutin, hesperidin, and quercetin (study group, SG), and 76 a mixture of diosmin in combination with hesperidin, diosmetin, isoroifolin, and linarin in purified micronized fraction (control group, CG). Bleeding, number of pathological piles, and Golligher’s grade were assessed at each scheduled visit and compared using the Chi-square test. During the study period, bleeding improved after 1 and 6 months both in the SG (79.5 and 70.5%) and in the CG (80.2 and 75%) without significant differences between two groups. Satisfaction degree after 6 months was greater in the patients of the SG (4.05) towards the CG (3.25): this result was statistical significant (p 0.003).


Use of flavonoids mixture (diosmin, troxerutin, rutin, hesperidin, quercetin) is a safe and effective mean of managing bleeding from hemorrhoidal disease and minimal adverse events are reported.


Hemorrhoids Therapy Flavonoids Anal bleeding 


  1. 1.
    Lohsiriwat V (2015) Treatment of hemorrhoids: a coloproctologist’s view. World J Gastroenterol 21:9245–9252CrossRefGoogle Scholar
  2. 2.
    Alonso-Coello P, Zhou Q, Martinez Zapata MJ, Mills E, Heels Ansdell D, Johanson JF, Guyatt G (2006) Meta analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 93:909–920CrossRefGoogle Scholar
  3. 3.
    Meyer OC (1994) Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 45:579–584CrossRefGoogle Scholar
  4. 4.
    Altomare DF, Roveran A, Pecorella G, Gaj F, Stortini E (2006) The treatment of hemorrhoids: guidelines of the Italian Society of Colorectal Surgery. Tech Coloproctol 10:181–186CrossRefGoogle Scholar
  5. 5.
    Rivadeneira DE, Steele SR, Ternent C (2011) Practice parameters for the management of hemorrhoids. Dis Colon Rectum 54:1059–1064CrossRefGoogle Scholar
  6. 6.
    Thomson WH (1975) The nature and cause of haemorrhoids. Proc R Soc Med 68:574–575PubMedPubMedCentralGoogle Scholar
  7. 7.
    Longo A (2002) Stapled anopexy and stapled hemorrhoidectomy: two opposite concepts and procedures. Dis Colon um 45:571–572CrossRefGoogle Scholar
  8. 8.
    Alonso-Coello P, Zhou Q, Martinez-Zapata MJ, Mills E, Heels-Ansdell D, Johanson JF (2006) Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 93:909–920CrossRefGoogle Scholar
  9. 9.
    Jiang ZM, Cao JD (2006) The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes. Curr Med Res Opin 22:1141–1147CrossRefGoogle Scholar
  10. 10.
    Ba-bai-ke-re MM, Huang HG, Re WN, Fan K, Chu H, Ai EH (2011) How we can improve patients’ comfort after Milligan-Morgan open haemorrhoidectomy. World J Gastroenterol 17:1448–1156CrossRefGoogle Scholar
  11. 11.
    Misra MC, Parshad R (2000) Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surg 87:868–872CrossRefGoogle Scholar
  12. 12.
    Perera N, Liolitsa D, Iype S, Croxford A, Yassin M, Lang P, Ukaegbu O, van Issum C (2012). Phlebotonics for haemorrhoids. Cochrane Database Syst Rev, 2012 Aug 15;(8):CD004322.Google Scholar
  13. 13.
    Ho Y-H, Tan M, Seow-Choen F (2000) Micronized purified flavonoid fraction compared favorably with rubber band ligation and fiber alone in the management of bleeding hemorrhoids: randomized controlled trial. Dis Colon Rectum 43:66–69CrossRefGoogle Scholar
  14. 14.
    Alonso P, Marzo M, Mascort JJ, Hervas A, Vinas L, Ferrus J (2002) Clinical practice guidelines for the management of patients with rectal bleeding. Gastroenterol Hepatol 25:605–632CrossRefGoogle Scholar
  15. 15.
    Madoff RD, Fleshman JW, Clinical Practice Committee, American Gastroenterological Association (2004) American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology 126:1463–1473CrossRefGoogle Scholar
  16. 16.
    Cospite M (1994) Double blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 in the treatment of acute hemorrhoids. Angiology 45:566–573CrossRefGoogle Scholar
  17. 17.
    Godeberge PH (1992) Daflon 500 is significantly more effective than placebo in the treatment of hemorrhois. Phlebology 7:61–63Google Scholar
  18. 18.
    Thanapongsathorn W, Vajrabukka T (1992) Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids. Dis Colon Rectum 35:1085–1088CrossRefGoogle Scholar
  19. 19.
    Shelygin Y, Krivokapic Z, Frolov SA, Kostarev IV, Astashov VL, Vasiliev SV, Lakhin AV, Rodoman GV, Soloviev AO, Stoyko YM, Khitaryan AG, Nechay IA (2016) Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease. Curr Med Res Opin 32:1821–1826CrossRefGoogle Scholar
  20. 20.
    Meshikhes AW (2004) Daflon for haemorrhoids: a prospective, multi-centre observational study. Surgeon 2:335–338CrossRefGoogle Scholar
  21. 21.
    Lyseng-Williamson KA, Perry CM (2003) Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 63:71–100CrossRefGoogle Scholar
  22. 22.
    Burnier M (2000) Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 5(Suppl 1):S31–S34CrossRefGoogle Scholar
  23. 23.
    Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefGoogle Scholar
  24. 24.
    Beena J, Jimmy J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26:155–159CrossRefGoogle Scholar
  25. 25.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487–497CrossRefGoogle Scholar
  26. 26.
    Giannini I, Amato A, Basso L, Tricomi N, Marranci M, Pecorella G, Tafuri S, Pennisi D, Altomare DF (2015) Flavonoids mixture (diosmin, troxerutin, hesperidin) in the treatment of acute hemorrhoidal disease: a prospective, randomized, triple-blind, controlled trial. Tech Coloproctol 19:339–345CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.General Surgery UnitSS. Cosma e Damiano HospitalPesciaItaly
  2. 2.General, Emergency and Mini-invasive surgeryCareggi University HospitalFlorenceItaly
  3. 3.General Surgery UnitBorgo San Lorenzo HospitalBorgo San LorenzoItaly
  4. 4.Unit of General Surgery 2, Policlinico Le ScotteSienaItaly

Personalised recommendations